Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
Open Access
- 1 February 1997
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 75 (4) , 506-511
- https://doi.org/10.1038/bjc.1997.88
Abstract
5'-Deoxy-5-fluorouridine (5'-DFUR) and 1-(tetrahydro-2-furyl)-5-fluorouracil (tegafur), prodrugs of 5-fluorouracil (5-FU), are anticancer agents activated by thymidine phosphorylase (dThdPase). As it is well known that the levels of dThdPase are higher in tumours than in normal tissue, it should be advantageous to use such pyrimidine antimetabolites for the selective inhibition of tumour growth. However, tumours are not necessarily sensitive to 5'-DFUR and tegafur because their levels of dThdPase vary. In this study, we examined whether transfection of tumour cells with a human platelet-derived endothelial cell growth factor (PD-ECGF) complementary DNA (cDNA) expressing dThdPase would sensitize the cells to the cytotoxic effects of pyrimidine antimetabolites in vitro. A cDNA encoding PD-ECGF was transfected into PC-9 cells (human lung adenocarcinoma). The transfected cells, PC9-DPE2, had a more than 50 times higher activity of dThdPase than the parental PC-9 cells or control PC-9 cells transfected with the pcDNA3 vector alone (PC9-D1). They were more sensitive than parental PC-9 or PC9-D1 cells not only to 5'-DFUR and tegafur but also to 5-FU. In addition, we demonstrated that PC9-DPE2 cells are able to potentiate the cytotoxic effects of 5'-DFUR towards co-cultured parental PC-9 cells. This "bystander effect' did not require cell-cell contact. These results suggest that transfection of PD-ECGF (dThdPase) genes may be useful as a gene therapy strategy for cancer treatment.Keywords
This publication has 31 references indexed in Scilit:
- Expression of platelet‐derived endothelial cell growth factor/thymidine phosphorylase in human breast cancerInternational Journal of Cancer, 1995
- Cancer gene therapy: A bystander effect using the gap junctional pathwayMolecular Carcinogenesis, 1994
- The implications of angiogenesis for the biology and therapy of cancer metastasisCell, 1994
- Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 GeneHuman Gene Therapy, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activityBiochemistry, 1992
- Platelet-derived endothelial cell growth factor has thymidine phosphorylase activityBiochemical and Biophysical Research Communications, 1992
- Aberrant expression and function of gap junctions during carcinogenesis.Environmental Health Perspectives, 1991
- Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.CHEMICAL & PHARMACEUTICAL BULLETIN, 1983
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976